Advertisement
Screener

YARROW BIOSCIENCE, INC. (YARW) Increase (Decrease) in Deferred Revenue

2.8 / 5 stars · 68/120 Roast Me

YARROW BIOSCIENCE, INC. Increase (Decrease) in Deferred Revenue

YARROW BIOSCIENCE, INC. (YARW) reported Increase (Decrease) in Deferred Revenue of -$8.53 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-07.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-11-07

  • YARROW BIOSCIENCE, INC. increase (decrease) in deferred revenue for the quarter ending 2018-09-30 was $0.00.
  • YARROW BIOSCIENCE, INC. increase (decrease) in deferred revenue for the quarter ending 2018-06-30 was -$8.08M.
  • YARROW BIOSCIENCE, INC. increase (decrease) in deferred revenue for the quarter ending 2018-03-31 was -$449.00K.
  • YARROW BIOSCIENCE, INC. increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was -$449.00K.
  • YARROW BIOSCIENCE, INC. increase (decrease) in deferred revenue for fiscal 2017 was -$1.80M, a 117.39% decline from fiscal 2016.
  • YARROW BIOSCIENCE, INC. increase (decrease) in deferred revenue for fiscal 2016 was $10.33M, a 28586.11% increase from fiscal 2015.
  • YARROW BIOSCIENCE, INC. increase (decrease) in deferred revenue for fiscal 2015 was $36.00K.
Period endIncrease (Decrease) in Deferred Revenue 3 monthIncrease (Decrease) in Deferred Revenue 6 monthIncrease (Decrease) in Deferred Revenue 9 monthIncrease (Decrease) in Deferred Revenue 12 month
2018-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07
-$8.08M
derived: sum of 2 quarters · filed 2018-11-07
-$8.53M
10-Q · filed 2018-11-07
-$8.98M
derived: sum of 4 quarters · filed 2018-11-07
2018-06-30-$8.08M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01
-$8.53M
10-Q · filed 2018-08-01
-$8.98M
derived: sum of 3 quarters · filed 2018-08-01
-$9.43M
derived: sum of 4 quarters · filed 2018-11-07
2018-03-31-$449.00K
10-Q · filed 2018-05-09
-$898.00K
derived: sum of 2 quarters · filed 2018-05-09
-$1.35M
derived: sum of 3 quarters · filed 2018-11-07
-$1.80M
derived: sum of 4 quarters · filed 2018-11-07
2017-12-31-$449.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-28
-$898.00K
derived: sum of 2 quarters · filed 2018-11-07
-$1.35M
derived: sum of 3 quarters · filed 2018-11-07
-$1.80M
10-K · filed 2018-03-28
2017-09-30-$449.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07
-$898.00K
derived: sum of 2 quarters · filed 2018-11-07
-$1.35M
10-Q · filed 2018-11-07
2017-06-30-$449.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01
-$898.00K
10-Q · filed 2018-08-01
2017-03-31-$449.00K
10-Q · filed 2018-05-09
2016-12-31$10.33M
10-K · filed 2018-03-28
2015-12-31$36.00K
10-K · filed 2018-03-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
PLIANT THERAPEUTICS, INC. (PLRX)United States$0.071B-0.76
TENAX THERAPEUTICS, INC. (TENX)United States$0.071B-7.17
Connect Biopharma Holdings Ltd (CNTB)$0.069B-2.17
PMV Pharmaceuticals, Inc. (PMVP)United States$0.071B-0.95
Lunai Bioworks Inc. (LNAI)United States$0.072B-0.11
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41
Cingulate Inc. (CING)United States$0.073B-2.64
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57
XBiotech Inc. (XBIT)United States$0.066B-1.56
HYPERION DEFI, INC. (HYPD)United States$0.065B